Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 6/20 | 1.00 |
| ▸ | AGL | P35573 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | GBA1 | P04062 | 2/20 | 1.00 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 1.00 |
| ▸ | MGAM | O43451 | 5/20 | 0.93 |
| ▸ | FUCA1 | P04066 | 5/20 | 0.93 |
| ▸ | GANC | Q8TET4 | 2/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19745374 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL19557590 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL15593220 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13317732 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL10028909 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL14268489 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL4319863 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL466573 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL13848041 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 | |
| SCHEMBL2434435 | 1.00 | GLA (1.00) | GLAAGLGAAGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | claimed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | claimed |
| EP-3086784-B9 | BICALUTAMIDE ANALOGS OR (S)-BICALUTAMIDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES SA (ES) | 2019-10-16 | — | — | EP | claimed |
| EP-3086784-B1 | BICALUTAMIDE ANALOGS OR (S)-BICALUTAMIDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES SA (ES) | 2019-03-27 | — | — | EP | claimed |
| US-20160317489-A1 | Bicalutamide Analogs Or (S)-Bicalutamide As Exocytosis Activating Compounds For Use In The Treatment Of A Lysosomal Storage Disorder Or Glycogenosis | BCN PEPTIDES, S.A. (ES) | 2016-11-03 | — | — | US | claimed |
| EP-3086784-A1 | BICALUTAMIDE ANALOGS OR (S)-BI CALUTAM IDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN Peptides, S.A. (ES) | 2016-11-02 | — | — | EP | claimed |
| WO-2015097088-A1 | BICALUTAMIDE ANALOGS OR (S)-BI CALUTAM IDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES, S.A. (ES) | 2015-07-02 | — | — | WO | claimed |
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | BCN PEPTIDES, S.A. (ES) | 2023-02-07 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| CN-105828811-B | Bicalutamide analogs or (S) -bicalutamide as exocytosis activating compounds for use in the treatment of lysosomal storage disorders or glycogen storage diseases | BCN肽类股份有限公司 | 2022-04-08 | — | — | CN | disclosed |
| US-10995067-B2 | Treatment of Fabry disease | ACADEMIA SINICA (TW) | 2021-05-04 | — | — | US | disclosed |
| WO-2020023390-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| US-20160317489-A1 | Bicalutamide Analogs Or (S)-Bicalutamide As Exocytosis Activating Compounds For Use In The Treatment Of A Lysosomal Storage Disorder Or Glycogenosis | BCN PEPTIDES, S.A. (ES) | 2016-11-03 | — | — | US | disclosed |
| EP-3086784-A1 | BICALUTAMIDE ANALOGS OR (S)-BI CALUTAM IDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN Peptides, S.A. (ES) | 2016-11-02 | — | — | EP | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME CORP. | 2015-10-01 | — | — | US | disclosed |
| WO-2015097088-A1 | BICALUTAMIDE ANALOGS OR (S)-BI CALUTAM IDE AS EXOCYTOSIS ACTIVATING COMPOUNDS FOR USE IN THE TREATMENT OF A LYSOSOMAL STORAGE DISORDER OR GLYCOGENOSIS | BCN PEPTIDES, S.A. (ES) | 2015-07-02 | — | — | WO | disclosed |
| WO-2014032188-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | ALECTOS THERAPEUTICS INC. (CA) | 2014-03-06 | — | — | WO | disclosed |
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | SUMMIT CORPORATION PLC (GB) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237538-A1 | TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND OTHER PROTEOSTATIC DISEASES | GAA, MAN2B1, GBA1 | GLA 13/4885AGL 71/4885GAA 1/4885 |
| US-11571407-B2 | Bicalutamide analogs or (S)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis | GBA1, GAA, GBA3 | GLA 11/4885AGL 41/4885GAA 2/4885 |
| US-20160317489-A1 | Bicalutamide Analogs Or (S)-Bicalutamide As Exocytosis Activating Compounds For Use In The Treatment Of A Lysosomal Storage Disorder Or Glycogenosis | GBA1, GAA, GBA3 | GLA 10/4885AGL 27/4885GAA 2/4885 |
| US-20150274656-A1 | GLYCOSIDASE INHIBITORS AND USES THEREOF | OGA, ENGASE, OGT | GLA 43/4885AGL 106/4885GAA 6/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | GLA 9/4885AGL 48/4885GAA 1/4885 |
| US-10995067-B2 | Treatment of Fabry disease | GBA2, GBA1, GAA | GLA 6/4885AGL 490/4885GAA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.